PROM1 and glioma: For instance, research by Zhu et al. demonstrated that CAR-T cells targeting CD133 effectively kill CD133+ CSCs in glioma patients, both in vitro and in vivo.776 However, such therapies have not succeeded in completely eradicating tumors, possibly due to tumor cell-induced terminal differentiation or senescence of CAR-T cells.